Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment.
5-Hydroxytryptamine (5-HT) receptor binding was determined in intact human platelets using 125I-iodolysergic acid diethylamide (125I-iodoLSD). The assay revealed that platelets possess a single population of specific binding sites for 125I-iodoLSD which have a high affinity for the 5-HT2 receptor antagonists, ketanserin and spiperone. There was no difference in platelet 125I-iodoLSD receptor binding between depressed patients and controls. However, treatment with tricyclic antidepressants increased the number of 125I-iodoLSD receptor binding sites without significantly altering their affinity.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000493:pharmacokinetics*; D001665:Binding Sites / Q000187:drug effects; D001792:Blood Platelets / Q000378:metabolism; D003866:Depressive Disorder / Q000378:metabolism*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011985:Receptors, Serotonin / Q000378:metabolism*
D000929:Antidepressive Agents, Tricyclic; D007457:Iodine Radioisotopes; C031182:LSD receptor; D011985:Receptors, Serotonin